Back to search results

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Pancreatic Adenocarcinoma Metastatic · Pancreatic Ductal Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Clínica Universidad de Navarra, Pamplona, Navarre, Spain

  • Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain

  • Hospital de Galdakao, Galdakao, Vizcaya, Spain

  • Fundación Jiménez-Díaz, Madrid, Spain

  • Hospital Universitario de Araba, Vitoria-Gasteiz, Álava, Spain

Study leads

  • Mariano Ponz Sarvisé, MD, PhD

    Principal Investigator

    Clinica Universidad de Navarra, Universidad de Navarra

  • Patricia Seoane Couselo, MD

    Principal Investigator

    Hospital Universitario de Araba

  • Fernando Garicano Goldáraz, MD

    Principal Investigator

    Hospital de Galdakao

  • Alberto Muñoz Llarena, MD

    Principal Investigator

    Hospital Universitario de Cruces

  • Ángela Lamarca Lete, MD, PhD

    Principal Investigator

    Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

View source on ClinicalTrials.gov(opens in a new tab)